Purvalanol B

SKU: orb1300012

Description

Purvalanol B is a potent and selective ATP-competitive inhibitor of cyclin-dependent kinases (CDKs), including Cdk2/cyclin A, Cdk2/cyclin E, Cdk5/p35, and Cdk2/cyclin B with IC50 values in the single-digit nanomolar range. This cell-permeable compound is widely used in biochemical and cellular research to study cell cycle progression, neuronal function, and apoptosis in various cancer and neurobiology models.

Research Area

Cell Biology, Infectious Disease & Virology

Key Properties

• CAS Number: 212844-54-7
• MW: 432.9
• Purity: 98.00%
• Formula: C₂₀H₂₅ClN₆O₃
• SMILES: CC(C)[C@H](CO)Nc1nc(Nc2ccc(C(O)=O)c(Cl)c2)c2ncn(C(C)C)c2n1
• Target: Parasite,CDK
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (4.62 mM);DMSO:40 mg/mL (92.4 mM)

Bioactivity

• Target IC50:
  CDK2-CyclinA:6 nM |CDK2-CyclinE:9 nM |CDK5-p35:6 nM |CDK2-CyclinB:6 nM
• In Vivo:
  Purvalanol B application decreases the ability of late-stage P.falciparum trophozoites to form multinucleated schizonts and up-regulates proteasome subunits and proteins that contribute to redox homeostasis, which may indicate an increase in oxidative stress as a result of inhibitor application.
• Animal Research:
  A SYBR Green I parasite growth assay was used to measure the IC50 of Purvalanol B with P. falciparum (strain W2). Purvalanol B or DMSO control were applied to synchronized parasites 36 hours post invasion and parasites were incubated for 12 hours. Giemsa-stained blood smears were used to determine the effect of Purvalanol B on parasite growth, global quantitative proteomic analysis was used to examine differences in protein expression between Purvalanol B-treated and control parasites and results were confirmed by qPCR.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Parasite, NG95, NG-95, NG 95, inhibit, Inhibitor, CDK5, CDK, CDK2, cdc2, Cyclin dependent kinase, cyclin, ATP, P. falciparum, p35, Purvalanol B

Compound Identifiers

PubChem CID

448991